Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATAINASDAQ:BNTCNASDAQ:IMUXNASDAQ:MREO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIAtai Life Sciences$2.06+2.0%$1.47$1.03▼$2.57$412.70M1.221.58 million shs1.71 million shsBNTCBenitec Biopharma$13.19-2.9%$13.54$5.74▼$16.90$337.66M0.3441,153 shs36,388 shsIMUXImmunic$0.92-0.3%$1.04$0.83▼$2.11$87.92M1.73719,429 shs445,534 shsMREOMereo BioPharma Group$2.24-1.8%$2.29$1.58▼$5.02$362.52M0.531.12 million shs568,594 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIAtai Life Sciences+1.98%+24.85%+35.53%+3.52%+23.35%BNTCBenitec Biopharma-2.94%-3.01%-3.44%+16.73%+38.99%IMUXImmunic-0.34%-4.52%-16.58%-27.06%-27.75%MREOMereo BioPharma Group-1.75%0.00%-12.50%-21.54%-25.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATAIAtai Life Sciences2.2985 of 5 stars3.71.00.00.02.52.50.6BNTCBenitec Biopharma2.2377 of 5 stars3.62.00.00.02.72.50.0IMUXImmunic2.3654 of 5 stars3.63.00.00.02.50.80.6MREOMereo BioPharma Group1.9169 of 5 stars3.62.00.00.02.31.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATAIAtai Life Sciences 3.33Buy$8.67320.71% UpsideBNTCBenitec Biopharma 3.22Buy$24.7187.37% UpsideIMUXImmunic 3.25Buy$13.001,316.74% UpsideMREOMereo BioPharma Group 3.25Buy$7.71244.39% UpsideCurrent Analyst Ratings BreakdownLatest IMUX, BNTC, MREO, and ATAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025IMUXImmunicB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $5.005/20/2025ATAIAtai Life SciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$5.005/20/2025ATAIAtai Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/19/2025BNTCBenitec BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.005/16/2025IMUXImmunicWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/15/2025BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.005/13/2025ATAIAtai Life SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.005/1/2025IMUXImmunicHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/30/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/16/2025IMUXImmunicB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATAIAtai Life Sciences$1.86M221.52N/AN/A$1.47 per share1.40BNTCBenitec Biopharma$80K4,220.80N/AN/A$3.24 per share4.07IMUXImmunicN/AN/AN/AN/A$0.64 per shareN/AMREOMereo BioPharma Group$1M356.16N/AN/A$0.36 per share6.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATAIAtai Life Sciences-$40.22M-$0.91N/AN/AN/AN/A-65.75%-52.71%8/12/2025 (Estimated)BNTCBenitec Biopharma-$21.75M-$1.51N/AN/AN/AN/A-44.61%-41.25%N/AIMUXImmunic-$93.61M-$1.23N/AN/AN/AN/A-169.55%-118.96%N/AMREOMereo BioPharma Group-$29.47M-$0.07N/AN/AN/AN/AN/AN/A8/12/2025 (Estimated)Latest IMUX, BNTC, MREO, and ATAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025IMUXImmunic-$0.25-$0.25N/A-$0.25N/AN/A5/14/2025Q1 2025ATAIAtai Life Sciences-$0.19-$0.15+$0.04-$0.15N/A$1.56 million5/14/2025Q3 2025BNTCBenitec Biopharma-$0.36-$0.24+$0.12-$0.24N/AN/A5/13/2025Q1 2025MREOMereo BioPharma Group-$0.01-$0.02-$0.01-$0.02$72.50 millionN/A3/26/2025Q4 2024MREOMereo BioPharma Group$0.02-$0.01-$0.03-$0.01$72.50 millionN/A3/17/2025Q4 2024ATAIAtai Life Sciences-$0.14-$0.24-$0.10-$0.24$0.30 million($0.01) millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATAIAtai Life SciencesN/AN/AN/AN/AN/ABNTCBenitec BiopharmaN/AN/AN/AN/AN/AIMUXImmunicN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATAIAtai Life Sciences0.145.815.81BNTCBenitec BiopharmaN/A25.4815.01IMUXImmunicN/A2.712.71MREOMereo BioPharma GroupN/A6.106.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATAIAtai Life Sciences28.41%BNTCBenitec Biopharma52.19%IMUXImmunic51.82%MREOMereo BioPharma Group62.83%Insider OwnershipCompanyInsider OwnershipATAIAtai Life Sciences31.20%BNTCBenitec Biopharma1.30%IMUXImmunic3.00%MREOMereo BioPharma Group5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATAIAtai Life Sciences80200.34 million115.45 millionOptionableBNTCBenitec Biopharma2025.60 million23.15 millionNo DataIMUXImmunic7095.82 million87.38 millionOptionableMREOMereo BioPharma Group40159.00 million148.74 millionOptionableIMUX, BNTC, MREO, and ATAI HeadlinesRecent News About These CompaniesTema Etfs LLC Invests $3.12 Million in Mereo BioPharma Group plc (NASDAQ:MREO)May 20, 2025 | marketbeat.comMereo BioPharma Group (MREO) to Release Earnings on WednesdayMay 19, 2025 | americanbankingnews.comMREO FY2025 EPS Estimate Increased by Cantor FitzgeraldMay 18, 2025 | americanbankingnews.comLeerink Partnrs Issues Negative Outlook for MREO EarningsMay 17, 2025 | americanbankingnews.comJanus Henderson Group PLC Boosts Stock Holdings in Mereo BioPharma Group plc (NASDAQ:MREO)May 16, 2025 | marketbeat.comMereo BioPharma Group (MREO) to Release Quarterly Earnings on WednesdayMay 16, 2025 | marketbeat.comWhy Mereo BioPharma Group plc’s (MREO) Stock Is Down 5.63%May 16, 2025 | aaii.comWe're Not Very Worried About Mereo BioPharma Group's (NASDAQ:MREO) Cash Burn RateMay 15, 2025 | finance.yahoo.comMereo BioPharma Group (NASDAQ:MREO) Receives "Buy" Rating from Needham & Company LLCMay 15, 2025 | marketbeat.comMereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate HighlightsMay 13, 2025 | finanznachrichten.deMereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate HighlightsMay 13, 2025 | globenewswire.comSchonfeld Strategic Advisors LLC Purchases Shares of 493,900 Mereo BioPharma Group plc (NASDAQ:MREO)May 8, 2025 | marketbeat.com225,000 Shares in Mereo BioPharma Group plc (NASDAQ:MREO) Purchased by Cantor Fitzgerald L. P.May 7, 2025 | marketbeat.comMereo BioPharma Group plc (NASDAQ:MREO) Given Average Rating of "Buy" by BrokeragesMay 6, 2025 | marketbeat.comAcuta Capital Partners LLC Sells 481,392 Shares of Mereo BioPharma Group plc (NASDAQ:MREO)May 4, 2025 | marketbeat.com683 Capital Management LLC Trims Stock Holdings in Mereo BioPharma Group plc (NASDAQ:MREO)May 4, 2025 | marketbeat.comMereo acquires Dish FiberMay 2, 2025 | advanced-television.comMarshall Wace LLP Lowers Stake in Mereo BioPharma Group plc (NASDAQ:MREO)April 29, 2025 | marketbeat.comMereo BioPharma Group plc (NASDAQ:MREO) Stock Position Lowered by Adage Capital Partners GP L.L.C.April 28, 2025 | marketbeat.comBlue Owl Capital Holdings LP Trims Stock Holdings in Mereo BioPharma Group plc (NASDAQ:MREO)April 26, 2025 | marketbeat.comWalleye Capital LLC Makes New Investment in Mereo BioPharma Group plc (NASDAQ:MREO)April 26, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMUX, BNTC, MREO, and ATAI Company DescriptionsAtai Life Sciences NASDAQ:ATAI$2.06 +0.04 (+1.98%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.09 +0.03 (+1.46%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Benitec Biopharma NASDAQ:BNTC$13.18 -0.41 (-3.01%) As of 05/23/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Immunic NASDAQ:IMUX$0.92 0.00 (-0.34%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.93 +0.01 (+1.24%) As of 05/23/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.Mereo BioPharma Group NASDAQ:MREO$2.24 -0.04 (-1.75%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.24 +0.00 (+0.22%) As of 05/23/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
